Cutaneous adverse drug reactions in a hospital-based Chinese population

Clinical and Experimental Dermatology

Volumn 36, Issue 2, 2011, Pages 135-141

  Huang, H Y ^a   Luo, X Q ^a   Chan, L S ^b   Cao, Z H ^a   Sun, X F ^a   Xu, J H ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMOXICILLIN; CARBAMAZEPINE; CEPHALOSPORIN;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANTICONVULSANT THERAPY; ARTICLE; CHINA; CONTROLLED STUDY; ERYTHEMA MULTIFORME; FEMALE; HOSPITALIZATION; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; URTICARIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLOPURINOL; ANALGESICS; ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; CHILD; CHINA; DRUG ERUPTIONS; ERYTHEMA MULTIFORME; EXANTHEMA; FEMALE; GOUT SUPPRESSANTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS; URTICARIA; YOUNG ADULT;

EID: 79951652223     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03922.x     Document Type: Article

References (25)

1. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123-9.
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
3. Roujeau JC, Bioulac-Sage P, Boursean C et al. Acute generalized exanthematous pustulosis Analysis of 63 cases. Arch Dermatol 1991; 127: 1333-8.
4. Alanko K, Stubb S, Kauppinen K. Cutaneous drug reactions: clinical types and causative agents A five-year survey of in patients (1981-1985). Acta Dermatol Venereol 1989; 69: 223-6.
5. Sacerdoti G, Vozza A, Ruocco V. Identifying skin reactions to drugs. Int J Dermatol 1993; 32: 469-79.
6. Breathnach SM, Philips WG. Epidemiology of bullous drug eruptions. Clin Dermatol 1993; 11: 441-7.
7. Stern RS, Wintroub B. Cutaneous reactions to drugs. In: Fitzpatrick's Dermatology in General Medicine (Freedberg IM, Eisen AZ, Wolff K et al., eds). New York: McGraw-Hill, 1999; 1633-42.
8. Puavilai S, Choonhakarn C. Drug eruptions in Bangkok: a 1-year study at Ramathibodi Hospital. Int J Dermatol 1998; 37: 747-51.
9. Naldi L, Conforti A, Venegoni M et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839-46.
10. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007; 56: 419-25.
11. Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
12. Yang GL, Wang XS. Modern Dermatology. Shanghai: Shanghai Medical School Press, 1995; 419.
13. Li LF, Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol 2006; 31: 642-7.
14. Patel RM, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venereol Leprol 2008; 74: 430.
15. Sushma M, Noel MV, Ritika MC et al. Cutaneous adverse drug reactions: a 9-year study from a South Indian Hospital. Pharmacoepidemiol Drug Saf 2005; 14: 567-70.
16. Gerson D, Sriganeshan V, Alexis JB. Cutaneous drug eruptions: a 5-year experience. J Am Acad Dermatol 2008; 59: 995-9.
17. Kamaliah MD, Zainal D, Mokhtar N, Nazmi N. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int J Dermatol 1998; 37: 520-3.
18. Lin MS, Dai YS, Pwu RF et al. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J 2005; 35: 188-90.
19. Aubock J, Fritsch P. Asymptomatic hyperuricemia and allopurinol induced toxic epidermal necrolysis. Br Med J 1985; 290: 1969-70.
20. Schneck J, Fagot JP, Sekula P et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
21. Sweetman S, ed. Martindale: The Complete Drug Reference. London: Pharmaceutical Press, 2006.
22. Devi K, George S, Criton S et al. Carbamazepine - the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol 2005; 71: 325-8.
23. Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 8: 486.
24. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
25. Dasgupta A. Review of abnormal laboratory test results and toxic effects due to use of herbal medicines. Am J Clin Pathol 2003; 120: 127-37.